COMMUNIQUÉS West-GlobeNewswire

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
15/11/2024
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously 23% of participants receiving [...]
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD)
15/11/2024
Phase 2 study results to be presented at The Liver Meeting ® 2024 of AASLD BJT-778 900 mg dosed every four weeks showed promising efficacy by Week 24: 100% virologic response with 50% of participants with undetectable [...]
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
15/11/2024
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. [...]
Iqirvo® (elafibranor) montre des données d’efficacité et de tolérance sur une période allant jusqu’à trois ans chez les patients atteints de CBP avec une amélioration de la fatigue et du prurit
15/11/2024
Ipsen met en avant 3 nouvelles présentations ainsi que 8 abstracts dans le cadre de son portefeuille de maladies cholestatiques rares du foie au congrès 2024 de l’AASLD. L’utilisation d’Iqirvo a été approuvée aux États- [...]
Eccogene Announces Positive Phase 1 Data for Oral THR-β Full Agonist and Oral SSAO Inhibitor in Late-Breaking Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®
15/11/2024
Both ECC4703 and ECC0509 demonstrated best-in-class potential, with favorable safety and tolerability profiles, clear target engagement and encouraging efficacy signals BOSTON and SHANGHAI, Nov. 15, 2024 (GLOBE NEWSWIRE [...]
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
15/11/2024
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage [...]
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
15/11/2024
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for [...]
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
15/11/2024
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide on co-morbidities of [...]
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
15/11/2024
The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations 1 In the [...]
The Testosterone Project Launches on National Testosterone Awareness Day, November 17
15/11/2024
New Nonprofit Founded by Leading Testosterone Experts Seeks to Provide Equal Access to Care for Both Men and Women RALEIGH, N.C., Nov. 15, 2024 (GLOBE NEWSWIRE) -- The Testosterone Project , a new nonprofit founded by [...]
Arthritis VIP Founder Dr. Mark Hawass Scoops Prestigious UK ‘Impact Award’
15/11/2024
LONDON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Dr. Mark Hawass, the trailblazing founder of Arthritis VIP , has been honoured with an esteemed ‘Impact Award’ from Big Business Events, the fastest-growing business coaching [...]
Organogenesis Commends Final LCDs
15/11/2024
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination CANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading [...]
LogicMark, Inc. Announces Reverse Stock Splits
15/11/2024
LOUISVILLE, Ky., Nov. 15, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK) (the “Company”), a provider of personal emergency response systems (PERS), health communications devices, and technology for the growing [...]
Trinity Biotech Announces Q3 2024 Financial Results
15/11/2024
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve [...]
Outset Medical to Present at the 2024 Stifel Healthcare Conference
15/11/2024
SAN JOSE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, [...]
Scientific Industries Reports Third Quarter 2024 Financial Results
15/11/2024
BIOPROCESSING OPERATIONS RECORDS 3 CONSECUTIVE QUARTERS OF REVENUE GROWTH OPERATIONAL EFFICIENCIES CUT QUARTER AND YTD NET LOSSES BY 46% AND 34% TWO MAJOR NEW PRODUCTS TO LAUNCH IN Q1 2025 Investor Call to be held [...]
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024
15/11/2024
PALO ALTO, Calif. , Nov. 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
15/11/2024
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for [...]
Samsung Bioepis Receives Positive CHMP Opinion for Denosumab Biosimilars, OBODENCE™ and XBRYK™
15/11/2024
OBODENCE™ and XBRYK™ recommended for approval by the European Medicines Agency for all indications referencing Prolia and Xgeva, respectively INCHEON, South Korea, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., [...]

Pages